Scaling up for success: from bioactive natural products to new medicines.


Journal

Natural product reports
ISSN: 1460-4752
Titre abrégé: Nat Prod Rep
Pays: England
ID NLM: 8502408

Informations de publication

Date de publication:
12 Aug 2024
Historique:
medline: 12 8 2024
pubmed: 12 8 2024
entrez: 12 8 2024
Statut: aheadofprint

Résumé

Covering 1986 to presentNatural product drug discovery at Novartis has a long and successful history of delivering life saving medicines to millions of patients. In this viewpoint, we are presenting the tools we use and challenges we face as we advance natural products from early research into development and beyond. We are leveraging our collection of 90 000 microbial strains and 20 000 isolated natural products to find new medications in an interdisciplinary approach that requires expertise in microbiology, computational biology, synthetic biology, chemistry, and process development. Technological advances, particularly in genome engineering and data science have transformed our field, accelerating discovery and facilitating sustainable compound supply. Emerging new modalities such as antibody drug conjugates, radioligand therapies and xRNA-based medications offer new opportunities for natural product-derived drugs. By taking advantage of these new modalities and the most recent research technologies, natural products will significantly contribute to the medicines of the future.

Identifiants

pubmed: 39129507
doi: 10.1039/d4np00022f
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Maximilian J Helf (MJ)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Kathrin Buntin (K)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Andrej Klančar (A)

Novartis d.o.o., Kolodvorska 27, 1234 Mengeš, Slovenija.

Michael Rust (M)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Frank Petersen (F)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Dominik Pistorius (D)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Eric Weber (E)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Joanne Wong (J)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Philipp Krastel (P)

Biomedical Research, Novartis Pharma AG, 4002 Basel, Switzerland. philipp.krastel@novartis.com.

Classifications MeSH